WO2011133668A3 - Methods and compositions for the treatment of cancer - Google Patents

Methods and compositions for the treatment of cancer Download PDF

Info

Publication number
WO2011133668A3
WO2011133668A3 PCT/US2011/033247 US2011033247W WO2011133668A3 WO 2011133668 A3 WO2011133668 A3 WO 2011133668A3 US 2011033247 W US2011033247 W US 2011033247W WO 2011133668 A3 WO2011133668 A3 WO 2011133668A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
cancer
genes
methods
biological activity
expression level
Prior art date
Application number
PCT/US2011/033247
Other languages
French (fr)
Other versions
WO2011133668A2 (en )
Inventor
Joan S. Brugge
Taru Muranen
Gordon Mills
Laura Selfors
Original Assignee
President And Fellows Of Harvard College
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Methods for identifying a cancer in a subject by measuring the expression level or biological activity of the following genes or proteins encoded by said genes: mTOR or PI3K and of one or more of IGFIR, B-bcl-2, src, rsk, FAK, VEGF, and PERK in the sample; where a decrease in the expression level or biological activity of mTOR or PI3K, and an increase in the expression level or biological activity of one or more of IGFIR, bcl-2, src, rsk, FAK, VEGF, and PERK identifies a cancer in the subject, as well as pharmaceutical compositions, kits, and methods for treating a subject diagnosed with, or at risk of developing cancer, by administering inhibitors of said genes or proteins encoded by said genes.
PCT/US2011/033247 2010-04-20 2011-04-20 Methods and compositions for the treatment of cancer WO2011133668A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US32611110 true 2010-04-20 2010-04-20
US61/326,111 2010-04-20

Publications (2)

Publication Number Publication Date
WO2011133668A2 true WO2011133668A2 (en) 2011-10-27
WO2011133668A3 true true WO2011133668A3 (en) 2011-12-15

Family

ID=44834784

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/033247 WO2011133668A3 (en) 2010-04-20 2011-04-20 Methods and compositions for the treatment of cancer

Country Status (1)

Country Link
WO (1) WO2011133668A3 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5677972B2 (en) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド Human serum albumin linkers and conjugates thereof
JP2013501808A (en) * 2009-08-12 2013-01-17 ポニアード ファーマシューティカルズ, インコーポレイテッド How to promote apoptosis and inhibit metastasis
CN103168037A (en) 2010-06-30 2013-06-19 博尼亚德医药品股份有限公司 Synthesis and use of kinase inhibitors
CA2825894A1 (en) 2011-02-02 2012-08-09 Amgen Inc. Prognosis of cancer using a circulating biomarker
CA2867349A1 (en) * 2012-03-15 2013-09-19 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors
US20150202287A1 (en) * 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
EP2890370A4 (en) 2012-08-31 2016-09-28 Univ California Agents useful for treating obesity, diabetes and related disorders
US9561245B2 (en) 2012-09-06 2017-02-07 The Board Of Regents Of The University Of Texas System Combination treatments for melanoma
CN103664935A (en) * 2012-09-17 2014-03-26 杨育新 Compounds for treating traumatic brain injury diseases and application thereof
WO2014137946A1 (en) * 2013-03-04 2014-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of inhibiting igf-1r activation or downtream signalling thereof to reduce radiation-induced cellular senescence
US9572828B2 (en) 2013-07-18 2017-02-21 The Board Of Regents Of The University Of Texas System Treatment for melanoma
WO2015054477A1 (en) * 2013-10-09 2015-04-16 The General Hospital Corporation Methods of diagnosing and treating b cell acute lymphoblastic leukemia
CN103908452A (en) * 2014-02-18 2014-07-09 广州金域医学检验中心有限公司 Composite drug and medicinal preparation for inhibiting lung cancer cell metastasis and detection method for lung cancer cell metastasis
CN103784460A (en) * 2014-02-18 2014-05-14 广州金域医学检验中心有限公司 Combined drug for inhibiting lung carcinoma cell migration, pharmaceutical preparation and detection method
WO2016007945A1 (en) * 2014-07-11 2016-01-14 Genesys Research Institute Compositions and methods for treating or preventing cardiac hypertrophy
CA2959347A1 (en) * 2014-08-25 2016-03-03 Salk Institute For Biological Studies Novel ulk1 inhibitors and methods using same
EP3144014A8 (en) * 2015-09-21 2017-04-26 Commissariat A L'energie Atomique Et Aux Energies Alternatives A synthetic lethal drug combination for treating renal cell carcinoma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109163A1 (en) * 2007-03-07 2008-09-12 Abraxis Bioscience, Llc. Nanoparticle comprising rapamycin and albumin as anticancer agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109163A1 (en) * 2007-03-07 2008-09-12 Abraxis Bioscience, Llc. Nanoparticle comprising rapamycin and albumin as anticancer agent

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CARBONI ET AL.: 'BMS-754807, a small molecule inhibitor of isulin-like growth factor IR/IR' MOLECULAR CANCER THERA. vol. 8, 2009, pages 3341 - 3349 *
DEBNATH ET AL.: 'Akt Activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner.' JOUMAL OF CELL BIOLOGY vol. 163, 2003, pages 315 - 326 *
LEE ET AL.: 'Adenovirus expressing shRNA to IGF-1 R enhances the chemosensitivity of lung cancer cell lines by blocking IGF-1 pathway.' LUNG CANCER vol. 55, no. 3, 2007, pages 279 - 86 *
MA ET AL.: 'Novel Agents on the Horizon for Cancer Therapy.' CANCER JOUMAL CLINICAL vol. 59, 2009, pages 111 - 137 *
YUAN ET AL.: 'Dual silencing of type 1 insulin-like growth factor and epidermal growth factor receptors to induce apoptosis of nasopharyngeal cancer cells.' J LARYNGOL OTOL. vol. 122, no. 9, 2008, pages 952 - 960 *

Also Published As

Publication number Publication date Type
WO2011133668A2 (en) 2011-10-27 application

Similar Documents

Publication Publication Date Title
Salphati et al. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel PI3K inhibitor 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno [3, 2-d] pyrimidine (GDC-0941)
Zhang et al. Roles of microRNA-34a targeting SIRT1 in mesenchymal stem cells
Zhang et al. Histone deacetylase inhibitors induce autophagy through FOXO1-dependent pathways
Komala et al. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice
Langevin et al. Leukocyte-adjusted epigenome-wide association studies of blood from solid tumor patients
Kojic et al. Anaplastic thyroid cancer: a comprehensive review of novel therapy
WO2011070499A1 (en) Phosphatidylinositol-3-kinase pathway biomarkers
Liao et al. Tryptanthrin inhibits angiogenesis by targeting the VEGFR2-mediated ERK1/2 signalling pathway
Maiello et al. EGFR and MEK blockade in triple negative breast cancer cells
Peng et al. Mechanisms of GOLPH3 associated with the progression of gastric cancer: a preliminary study
Krueger et al. A randomized, placebo-controlled study of SRT2104, a SIRT1 activator, in patients with moderate to severe psoriasis
Gupta et al. Efficacy of platelet-rich fibrin vs. enamel matrix derivative in the treatment of periodontal intrabony defects: a clinical and cone beam computed tomography study.
Miller et al. Chronic oral L-carnitine supplementation drives marked plasma TMAO elevations in patients with organic acidemias despite dietary meat restrictions
Crawford Clinical results in cachexia therapeutics
Martin et al. The synthetic antimicrobial peptide 19-2.5 interacts with heparanase and heparan sulfate in murine and human sepsis
Huang et al. RETRACTED ARTICLE: Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy
Leung et al. Evidence for the existence of triple-negative variants in the MCF-7 breast cancer cell population
Shen et al. N-acetylcysteine alleviates angiotensin II-mediated renal fibrosis in mouse obstructed kidneys
Sato et al. Impact of the Oral Adsorbent AST-120 on Organ-Specific Accumulation of Uremic Toxins: LC-MS/MS and MS Imaging Techniques
Siddappa et al. Curcumin and metformin‐mediated chemoprevention of oral cancer is associated with inhibition of cancer stem cells
Ito et al. Inflammation rapidly modulates the expression of ALDH1A1 (RALDH1) and vimentin in the liver and hepatic macrophages of rats in vivo
Zychowska et al. Spinal CCL1/CCR8 signaling interplay as a potential therapeutic target–evidence from a mouse diabetic neuropathy model
Tardelli et al. Adiponectin regulates aquaglyceroporin expression in hepatic stellate cells altering their functional state
Ataei et al. A double‐blind, randomized, controlled trial on N‐acetylcysteine for the prevention of acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation
Young et al. Regional differences in prostaglandin E 2 metabolism in human colorectal cancer liver metastases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11772633

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 11772633

Country of ref document: EP

Kind code of ref document: A2